本文已被：浏览 5195次 下载 0次
中文摘要: 目的：通过对比注射康柏西普后对非缺血型视网膜静脉阻塞患者视力的改善作用，评价康柏西普对本病的短期临床疗效、安全性及相关危险因素。方法：选取2016年12月至2017年12月从发现自觉症状到就诊的病程小于12个月的在我科就诊的病例，确诊为非缺血型视网膜静脉阻塞的患者（共43例），将所有研究对象根据病程长短，分为病程小于3个月组（A组）16例患者，病程3-6个月组（B组）13例患者，6-12 个月组（C组）14例患者。所有患者同时行玻璃体腔内注射康柏西普，三组均先注射1次，之后每1个月随访测定眼压、BCVA、CMT。结果：初诊视力与治疗后视力差异有统计学意义(P＜0.05）；初诊黄斑水肿高度与治疗后差异有统计学意义(P＜0.05）；性别、年龄与视力预后疗效无统计学意义（P>0.05）；治疗前的眼压相比较，三组内的各随访点均没有统计学差异（P>0.05）。结论：玻璃体腔内注射康柏西普治疗本病疗效确切；病程长短对本病的治疗效果有较大影响，越早期治疗效果越佳。
中文关键词: 非缺血性视网膜静脉阻塞 康柏西普 病程 视力
Abstract:Objective: To observe the short-term clinical efficacy and safety of intraperitoneal injection of conbercept in the treatment of non-ischemic retinal vein occlusion. 2 To explore the influencing factors of the efficacy of intraperitoneal injection of conbercept in the treatment of non-ischemic retinal vein occlusion. METHODS: Patients with non-ischemic retinal vein occlusion were diagnosed from December 2016 to December 2017 from patients with symptomatic symptoms to a clinic with a course of less than 12 months. All patients underwent vitreous cavity. Conbercept was injected, and all three groups were injected once. At the time of follow-up, the injection was repeated according to changes in visual acuity and OCT. Results: There was no statistically significant difference in gender, age and visual acuity. The prognosis of visual acuity and visual acuity was statistically significant (P <0.05). The initial macular edema height and visual prognosis were statistically significant (P<0.05). There was no significant difference in the intraocular pressure between the three groups (P>0.05). Conclusion: Intravitreal injection of conbercept is effective in the treatment of this disease, and the early treatment effect is better.
文章编号：3202003021 中图分类号：R774.1 文献标志码：
基金项目:
| 作者 | 单位 |
| 李雨佳①，张含① |
| Author Name | Affiliation |
引用文本：